Skip to main content
Clinical Trials/NCT01750164
NCT01750164
Terminated
Not Applicable

Patient Derived Breast Cancer Xenografts

Dartmouth-Hitchcock Medical Center1 site in 1 country1 target enrollmentDecember 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Metastatic Breast Cancer
Sponsor
Dartmouth-Hitchcock Medical Center
Enrollment
1
Locations
1
Primary Endpoint
Successful Engraftment
Status
Terminated
Last Updated
10 years ago

Overview

Brief Summary

This study will use tissue or body fluid acquired during standard procedures that are part of the patient's care for their cancer, such as surgery to remove tumor tissue or needle withdrawal of body fluid containing cancer cells. The tissue or cells will be injected into immune compromised mice and the tissue will be allowed to grow to a tumor 1-1.5 cm size. The tissue will then be extracted and either frozen, embedded in paraffin, or used for engraftment into another generation of mice. The second generation mice will be separated into groups and given various treatments.

Tissue from the participants and from the mouse established tumors, in which the mice have either received treatment or have not received treatment, will be used to evaluate the levels of various genes that assist in regulating cell growth and cell death. The tumor tissue from participants and mice will also be tested for random changes in the genetic material and compared to the participant's blood to determine if any of the changes in the genetic material correlate with better engraftment of the patient tissue in the mice. It is anticipated that 10-30% will have successful engraftment of tumor tissue

Registry
clinicaltrials.gov
Start Date
December 2013
End Date
August 2014
Last Updated
10 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Successful Engraftment

Time Frame: 2 years

Thirty-five patients with breast cancer will be recruited. We anticipate that 10-30% will have successful engraftment of tumor tissue. The achievement of five successful xenografts would justify additional study.

Secondary Outcomes

  • Time until tumor formation(2 years)

Study Sites (1)

Loading locations...

Similar Trials